Lithium - Articles - Page 3 | CARLAT PUBLISHING

CLINICAL UPDATE

Low-Dose Lithium to Delay Dementia?

September 1, 2022

James Phelps, MD. Psychiatrist Emeritus, Samaritan Mental Health, Corvallis, OR. Medical Director, PsychEducation.org. Dr. Phelps, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Current medications for dementia do little more than temporarily slow the cognitive decline, but new evidence suggests that tiny doses of lithium can significantly delay the onset.

CLINICAL UPDATE

Six Tips From Prescribing Psychotropics

August 1, 2022

Chris Aiken, MD

Chris Aiken, MD.

Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Aiken, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

New answers to age-old questions, such as adjusting the dose to account for drug interactions, reducing side effects, maintaining weight, and protecting that finicky organ—the kidneys.

Lithium Exposure In Utero—How Bad Is It Really?

July 1, 2022

Victoria Hendrick, MD and Lara Tang, MD

Lara Tang, MD, and Victoria Hendrick, MD. Dr. Tang and Dr. Hendrick have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We know prenatal lithium exposure increases the risk of heart defects in newborns. By keeping lithium doses and blood levels under certain cut-off points, we can reduce this risk, according to this large meta-analysis.

Sleepwalking on Antipsychotics and Lithium

November 5, 2021

Thomas Jordan, MD.

Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Sleepwalking is a rare side effect on psychiatric medications, particularly hypnotics and antidepressants. A new analysis explores whether lithium and the antipsychotics should be added to that list.

ECT Worked: Now What?

August 3, 2021

Michael Posternak, MD.

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Your patient has recovered from depression with ECT, but their chances of going back into it are high (80%). In this article, learn 3 ways to reduce that risk.

Maintenance Pharmacotherapy of Bipolar Disorder: How Long Is Long Enough?

May 4, 2021

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Textbooks tell us that patients with bipolar I disorder need to take mood stabilizers for life. But what are the real risks of stopping these medications? A new meta-analysis provides some clarity.

Which Medications Have the Lowest Risk of Side Effects?

October 30, 2020

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When we choose medications, we typically think that we are paying attention to risks and benefits. But what happens when we just look through the lens of side effects? An entirely different picture emerges of what medications might be the better picks. You will be surprised and intrigued by this review of a very helpful study that will probably change your prescribing patterns.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

Who Should Get Lithium?

September 3, 2020

Janusz Rybakowski, MD, PhD

Janusz Rybakowski, MD, PhD

Janusz Rybakowski is a pioneer in lithium research who has authored over 500 articles on clinical psychiatry. He is a professor of psychiatry at Poznan University in Poland, former chairman of psychiatry at the Medical Academy Bydgoszcz, and author of an upcoming textbook on lithium. Dr. Rybakowski has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.

RESEARCH UPDATE

Two Augmentation Strategies Compared in Bipolar I

September 3, 2020

Richard Moldawsky, MD

Richard J. Moldawsky, MD. Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.